Alvotech today announced the appointment of Mark Levick as Chief Executive Officer, effective 5 August 2019. Mark brings over 18 years of global industry experience, with a very impressive track record of value creation and success in bringing new biosimilars to market. Prior to joining Alvotech, Mark was the head of development of Sandoz biopharmaceuticals. He succeeds Rasmus Rojkjaer, who has stepped down from his role.